Hospital Universitario Rio Hortega — Clinical Trial Site

59 Registered trials

25 Currently recruiting

Organisation

Hospital Universitario Rio Hortega

Location

Valladolid, Spain

Identifier

ORG-100039573

Address

Calle Dulzaina 2, 47012, Spain

Departments

#3412 - Medicina interna
3412: Reumatología
Anestesiología y Reanimación
Aparato Digestivo
Autoinmmune Diseases
Cirugía
Cirugía general
Dermatology
Digestive
Digestivo
Endocrinología
Gastroenterology
Hematología
Hematology
Hepatology department
Hepatology Service
Hospital Rio Hortega (#1)
Intensive Medicine
Internal Medicine
Medical Doctor
Medicina interna
N/A
Neumología
Neurologia
Ophtalmology
Ophthalmology
Ophthalmology service
Psychiatry
Psychiatry and mental health
Psychiatry service
Pulmonology
Rheumatology
Serv. De Reumatología
Servicio de Gastroenterología y Hepatología
Servicio de Hematologica
Servicio de Medicina Interna
Surgery
Urology

Clinical trials at this site (59)

Search interface

A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adul… Recruiting

2023-504863-17-00 1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic 5 2024-02-21
A Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cut… Recruiting

2023-505634-94-00 Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneo 10 2023-02-02
“A Phase II, double-blinded, placebo-controlled clinical trial to evaluate the safety and efficacy of mesenchymal cells (MSV-ALLO®) in the t… Recruiting

2024-514750-67-00 Lupus Nephritis 10 2022-09-13
Multicentre Phase IV clinical trial to evaluate the efficacy of hyperthermic intraoperative chemotherapy (HIPEC) with Mitomycin-C after comp… Recruiting

2024-512726-28-00 peritoneal metastases of colorectal cancer 6 2022-02-14
Clinical study to demonstrate the same clinical efficacy and tolerability of budesonide orodispersible tablets (taken twice a day compared t… Recruiting

2024-515229-26-00 eosinophilic esophagitis 5 2021-05-21
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended

2025-521067-13-00 Atherosclerotic Cardiovascular Disease (ASCVD) 5 2026-04-24
A Study to Assess the Effectiveness and Safety of RO7790121 for Induction Therapy in Participants with Moderately to Severely Active Ulcerat… Ended

2024-513015-27-00 Moderately to Severely Active Ulcerative Colitis (UC) 5 2025-01-09
A research study to evaluate the efficacy and safety of cenerimod in subjects suffering from systemic lupus erythematosus Ended

2024-515871-37-00 Moderate to severe systemic lupus erythematosus 5 2024-10-24
A Phase III study to investigate two initial administrations of COMP360 in treatment-resistant depression Ended

2023-505268-12-00 Treatment-resistant depression 5 2024-02-09
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2) Ended

2022-500700-22-00 Active Systemic Lupus Erythematosus (SLE) 5 2023-05-25
A study to assess safety and efficacy of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis (PSC) Ended

2024-511370-72-00 Primary Sclerosing Cholangitis 4 2023-03-29
Phase 3 study to evaluate two regimens of ianalumab on top of standardof- care therapy in patients with systemic lupus erythematosus (SIRIUS… Ended

2023-508498-97-00 Systemic Lupus Erythematosus 5 2023-02-03
A Study to Evaluate Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related … Ended

2023-507131-38-00 Neovascular Age-Related Macular Degeneration (nAMD) 5 2022-05-16
Efficacy and safety of Frexalimab (SAR441344) in the treatment of Systemic Lupus Erythematosus Ended

2023-508654-26-00 Systemic lupus erythematosus 4 2022-03-15
Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROLled trial of therapeutic escalation, the POMEROL tri… Ended

2023-508242-18-00 Crohn's disease 6 2021-12-21
A Study to Evaluate the Efficacy and Safety of BIIB059 (Litifilimab) in Adult Participants With Active Systemic Lupus Erythematosus Receivin… Ended

2023-505695-30-00 systemic lupus erythematosus 5 2021-11-30
A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients … Ended

2023-507130-24-00 Neovascular age-related macular degeneration (nAMD) 5 2021-10-22
PEITHO-3 - A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism: a randomized controll… Ended

2024-511321-54-00 intermediate-high-risk acute pulmonary embolism 5 2021-08-04
Protocol Title: Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VI… Ended

2024-512075-12-00 hemophilia A 5 2021-06-14
A study to evaluate safety and efficacy of Empasiprubart in adults with Dermatomyositis Ended

2023-508337-14-00 Myositis, Dermatomyositis 4 2025-03-18
MLS-101-301: A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of … Ended

2023-506425-12-00 Uncontrolled and Resistant Hypertension 5 2024-04-17
A clinical study of MK-6194 for the treatment of Systemic Lupus Erythematosus (SLE) (MK-6194-006) Ended

2023-505520-61-00 Systemic Lupus Erythematosus 10 2024-03-11
THE ANTES B+ STUDY: AN OPEN-LABEL, PRAGMATIC, RANDOMIZED, CONTROLLED TRIAL OF TRIPLE THERAPY VERSUS LABA-LAMA COMBINATION TO IMPROVE CLINICA… Ended

2023-507304-32-00 Chronic Obstructive Pulmonary Disease 6 2024-02-09
A study to learn how well a higher amount of aflibercept given as an injection into the eye works and how safe it is in people with reduced … Ended

2022-502174-16-00 Macular edema secondary to retinal vein occlusion 5 2023-09-13